Dibotermin alfa
Inductos (dibotermin alfa) is a protein pharmaceutical. Dibotermin alfa was first approved as Inductos on 2002-09-09. It has been approved in Europe to treat internal fracture fixation, spinal fusion, and tibial fractures.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
39 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tibial fractures | D013978 | EFO_0003944 | S82.20 | — | — | — | 2 | — | 2 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intervertebral disc degeneration | D055959 | HP_0008419 | — | — | 1 | — | 11 | 12 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Periodontitis | D010518 | EFO_0000649 | K05.3 | — | 1 | — | — | 1 | 2 |
| Malocclusion | D008310 | M26.4 | — | 1 | — | — | — | 1 | |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bunion | D000071378 | M21.61 | 1 | — | — | — | — | 1 | |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 1 | — | — | — | — | 1 |
| Radius fractures | D011885 | EFO_0003957 | S52.37 | 1 | — | — | — | — | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | — | — | — | — | 1 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DIBOTERMIN ALFA |
| INN | nebotermin |
| Description | Inductos (dibotermin alfa) is a protein pharmaceutical. Dibotermin alfa was first approved as Inductos on 2002-09-09. It has been approved in Europe to treat internal fracture fixation, spinal fusion, and tibial fractures. |
| Classification | Protein |
| Drug class | growth factors: bone morphogenetic proteins; growth factors: transforming growth factors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2109171 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | T472P45MG6 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 119 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
787 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more